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ABSTRACT
Background and objective: Oxidative stress plays an
important role in the pathogenesis of chronic obstruc-
tive pulmonary disease (COPD). In this longitudinal
study changes in the level of malondialdehyde (MDA),
an end product of polyunsaturated fatty acid peroxida-
tion, were investigated in the airways of patients with
acute exacerbation of COPD (AECOPD).
Methods: Levels of MDA were measured in sputum
and exhaled breath condensate (EBC) of 34 COPD
patients at the time of hospital admission due to an
acute exacerbation of the disease, and again following
treatment at the time of hospital discharge. MDA was
also assessed in 21 stable patients with COPD and 20
healthy controls.Measurements were performed using
high-performance liquid chromatography.
Results: Sputum MDA levels were significantly
increased in AECOPD (220.0  17.5 nmol/L) compared
with stable disease (144.6  14.3 nmol/L,P < 0.01) and
healthy controls (85.9  11.3 nmol/L, P < 0.001).
MDA levels decreased after treatment (190.7 
16.3 nmol/L, P < 0.05). In contrast to sputum, EBC
MDA levels were comparable between controls, stable
COPD patients and AECOPD patients (73.1 
5.1 nmol/L, 96.1  11.6 nmol/L and 93.3  7.6 nmol/L,
P = NS). Measurement of MDA had good repeatability
in both sputumandEBC,but the between-day variabil-
ity was considerably higher in EBC. Sputum induction
did not influence MDA levels.
Conclusions: MDA in sputum, but not in EBC,
appears to be a useful marker for monitoring
exacerbation-associated oxidative stress in AECOPD.
Key words: chronic obstructive pulmonary disease, exhaled
breath condensate, oxidative stress, repeatability, sputum.
Abbreviations: AECOPD, acute exacerbation of chronic
obstructive pulmonary disease; COPD, chronic obstructive pul-
monary disease; CR, coefficient of repeatability; CV, coefficient of
variation; EBC, exhaled breath condensate; FENO, fractional
exhaled nitric oxide; FEV1, forced expiratory volume in one
second; FVC, forced vital capacity; HPLC, high-performance
liquid chromatography; MDA, malondialdehyde; NS, non-
significant; PaCO2, arterial carbon dioxide tension; PaO2, arterial
oxygen tension; WBC, white blood cell.
INTRODUCTION
Oxidative stress is thought to play a pivotal role in
the pathogenesis of chronic obstructive pulmonary
disease (COPD), particularly during acute exacerba-
tions of COPD (AECOPD).1–3 Several processes lead to
oxidative stress-related tissue damage, among them
lipid peroxidation, in which oxidation of cell mem-
brane phospholipids results in the formation of
various lipid hydroperoxides and aldehydic prod-
ucts.2 Among these molecules, malondialdehyde
(MDA), a by-product of polyunsaturated fatty acid
peroxidation, may be a reliable marker of oxidative
stress in various diseases.4
Sputum induction and exhaled breath condensate
(EBC) collection allow sampling of the airways in a
non-invasive fashion. Sputum and EBC have been
widely used to assess airway inflammation and oxida-
tive stress in COPD.5 Both methods offer a unique
opportunity to identify pulmonary biomarkers of
potential clinical utility in the management of COPD.6
There is evidence that MDA can be measured accu-
rately in EBC using high-performance liquid chroma-
tography (HPLC).7 Using this technique it was
recently demonstrated that MDA levels in EBC8,9 and
induced sputum10 are elevated in stable COPD
compared with levels in healthy controls. It should be
noted, however, that in some of these trials9,10 the
group with COPD included current smokers. The
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SUMMARY AT A GLANCE
Malondialdehyde, an established by-product of
lipid peroxidation, can be precisely measured in
the sputum and is a useful marker to monitor
exacerbation-associated oxidative stress in
patients with COPD.
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inclusion of smokers potentially affected the overall
outcome of the study, as it has been shown, at least in
EBC, that smoking alone increases MDA levels.8
The above-mentioned data suggest that MDA
measurements can discriminate between persons
with COPD and healthy subjects. However, the clini-
cal utility of the test for monitoring oxidative stress
during AECOPD is unclear. Moreover, it is unknown if
EBC or sputum has superior clinical utility in this
context.
In this longitudinal study we assessed the levels of
MDA in sputum and EBC of patients with AECOPD at
onset and after treatment. For comparison, MDA
levels in stable COPD and healthy controls were also
determined.
METHODS
Study subjects
Patients hospitalized with AECOPD were recruited for
the study. Inclusion and exclusion criteria for partici-
pation are summarized in Figure 1. Exacerbation was
defined as increased dyspnoea, cough or sputum
expectoration that led the subject to seek medical
attention, as specified in international guidelines.11
Additionally, 21 clinically stable ex-smoker COPD
patients and 20 healthy ex-smoker controls were
enrolled in the study (Table 1). All patients were >40
years of age, had a smoking history of >10 pack-years,
and also had documented airway obstruction, with
forced expiratory volume in one second (FEV1) < 80%
of predicted value and postbronchodilator FEV1/
forced vital capacity (FVC ratio) < 0.7. Control sub-
jects had normal lung function values and no history
of acute or chronic respiratory diseases in the previ-
ous 4 weeks. The local ethics committee approved the
research protocol, and all subjects gave written
informed consent to participate in the study.
Study design
In patients with AECOPD, EBC and spontaneously
expectorated sputum were collected and levels of
fractional exhaled nitric oxide (FENO), blood gases
and lung function parameters were measured on hos-
pital admission and on the day of discharge. In stable
COPD patients and healthy controls, EBC and
induced sputum samples were collected during
routine clinical visits. Lung function, blood gas
parameters and FENO were determined, as previ-
ously described.12
EBC collection
EBC was collected for a period of 10 min using an
EcoScreen condenser (Jaeger, Hoechberg, Germany),
as described previously.12 All samples were stored
frozen at -80°C before analysis.
Sputum induction and processing
In stable COPD patients sputum was induced by the
inhalation of a hypertonic saline solution (4% sodium
chloride) delivered by an ultrasonic nebulizer (Ultra-
Figure 1 Flow chart showing the study
profile in patients with acute exacerbation
of chronic obstructive pulmonary disease
(AECOPD).
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Neb 2000, DeVilbiss Healthcare Ltd, Tipton, UK) with
an output set at 1 mL/min.
Induced and spontaneous sputum samples were
processed similarly within 120 min from collection,
as previously described.13 Samples were homogenized
in PBS containing 0.1% dithiothreitol (DTT). Investi-
gating a subset of samples (n = 6) we found that DTT
has no effect on MDA assay (206.9  51.7 nmol/L
with DTT vs 145.2  26.7 nmol/L without DTT,
P = NS). At least 400 inflammatory cells were counted
for each cytospin slide. The number of inflammatory
cells in sputum was recorded as a percentage of total
viable non-squamous cells.
Measurement of MDA
MDA concentrations in EBC and sputum supernatant
were measured by an isocratic HPLC system using
MDA reagent kit (Chromsystems Ltd, Munich,
Germany), according to the method described by
Lärstad et al.7 Analysis was performed using a HPLC
unit with fluorescence detector (Jasco, FP-2020 Plus;
ABL&E-Jasco Ltd, Budapest, Hungary) equipped with
a MDA HPLC column (Chromsystems). Excitation
and emission wavelengths were 515 and 553 nm,
respectively. The flow rate was 1.0 mL/min. The limit
of quantification was 0.01 mmol/L.
In order to compare MDA levels in induced and
spontaneous sputum, a subgroup of stable COPD
patients (n = 10) capable of expectorating sputum
spontaneously were selected in a pilot study. MDA
concentrations in induced (135.7  9.7 nmol/L) and
spontaneous sputum samples (148.1  7.3 nmol/L)
collected from the same subjects were comparable
(P = NS). The coefficient of repeatability (CR) was
48.7 nmol/L. The limits of agreement were -30.8 and
55.7.
Intra- and inter-assay repeatability of
MDA measurements
In order to estimate the intra-assay repeatability of
MDA readings, a subset of processed and analysed
EBC (n = 12) and sputum (n = 12) samples derived
from six patients with stable COPD and six controls
were assessed. These samples were stored at 4°C for
two weeks and then remeasured by HPLC. For calcu-
lation of the inter-assay repeatability of MDA mea-
surements, sputum and EBC samples collected from a
subset of COPD patients (n = 12) were divided into
two aliquots, which were then processed and mea-
sured separately.
Between-day variability of MDA measurements
In order to assess the between-day variability of MDA
measurements, EBC and spontaneous sputum collec-
tions from the same subjects were repeated in a
subgroup of stable COPD patients (n = 12) on two
consecutive days.
Table 1 Demographic and clinical characteristics of study subjects
Healthy controls Stable COPD COPD exacerbation
Subjects, n 20 21 34
Sex, n
Male 10 13 20
Female 10 8 14
Age (years) 61.8  1.6 63.1  1.8 64.2  2.5
Smoking (pack-years) 51.6  5.2 39.5  3.9 40.5  4.2
GOLD stages, n (%)
I NA 4 (19) 2 (6)
II NA 12 (57) 10 (29)
III NA 5 (24) 15 (44)
IV NA 0 (0) 7 (21)
Pulmonary function At admission After treatment
FVC (L) 3.92  0.20 3.39  0.16 1.96  0.11 2.16  0.13#
FVC (% of predicted) 104.2  2.7 83.4  2.9 72.1  3.3 79.9  3.4##
FEV1 (L) 2.93  0.14 1.74  0.13 0.94  0.07 1.11  0.08##
FEV1 (% of predicted) 111.3  3.6 63.1  4.3** 43.7  2.85 51.9  3.10##
FEV1/FVC (%) 77.0  1.4 49.4  2.2** 0.48  0.02 0.52  0.02#
Blood gases
PaCO2 (kPa) 5.2  0.13 5.2  0.12 5.33  0.17 5.64  0.21
PaO2 (kPa) 10.3  0.73 8.4  0.22* 6.92  0.23 7.57  0.20#
FENO (ppb)† 7.1 (5.9–9.9) 8.7 (6.03–11.4) 12.7 (6.18–28.7) 10.2 (6.55–17.3)#
Data are presented as mean  SEM unless stated otherwise.
*P < 0.05 vs controls; **P < 0.001 vs controls; #P < 0.05 vs admission; ##P < 0.001 vs admission.
†Median (interquartile ranges).
COPD, chronic obstructive pulmonary disease; FENO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in one second;
FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Pulmonary Disease; PaCO2, arterial carbon dioxide tension;
PaO2, arterial oxygen tension; ppb, parts per billion.
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Statistical analysis
Data are presented as mean  SEM or median with
interquartile range as appropriate. MDA concentra-
tions were compared using one-way anova with
Newman–Keuls test for multiple comparisons. Paired
Student’s t-test (parametric data) and the Wilcoxon
signed-rank test (non-parametric data) were used to
compare measurements at the time of hospital
admission and measurements at discharge. Differ-
ences in baseline parameters between stable patients
and controls were analysed by unpaired t-test or the
Mann–Whitney test. Correlations were analysed by
Pearson’s method. The repeatability and variability of
MDA measurements were assessed using the coeffi-
cient of variation (CV) and the Bland–Altman test.
Additionally, the CR was estimated.14 Calculations
were performed with GraphPad Prism 4.0 (GraphPad
Software Inc., San Diego, CA, USA). A P-value < 0.05
was considered significant.
RESULTS
Fifty-four patients with AECOPD were screened; 44
fulfilled inclusion criteria and agreed to participate
(Fig. 1). During hospital treatment 10 patients were
withdrawn. Demographic and clinical data of the 34
patients who completed the study are presented in
Table 1.
Clinical variables during treatment of
exacerbations
Exacerbations were treated with systemic glucocorti-
coids and short-acting bronchodilators (anticholiner-
gics and/or b2-agonists) in all cases. In addition, 73%
of the patients received long-acting b2-agonists or
anticholinergics. Antibiotics were given to 19 patients.
The majority of patients (89%) were treated with
oxygen. The mean length of hospitalization was
10.9  1.5 days. During the course of treatment/
recovery lung function variables and PaO2 increased,
while sputum total cell counts and the number of
neutrophils significantly decreased (Table 1 and Sup-
porting Information Table S1).
Intra-assay repeatability of
MDA measurements
MDA levels in sputum or EBC did not change after the
processed samples had been kept at 4°C for 2 weeks
(P = NS) (Supporting Information Table S2). The
mean CV for repeated measurements and the limits
of agreement were similar between sputum and
EBC. The CR in sputum and EBC were 25.7 and
18.5 nmol/L, respectively.
Inter-assay repeatability of
MDA measurements
MDA concentrations in two aliquots of the same
sputum and EBC sample were similar (P = NS) (Sup-
porting Information Table S2). Again, the mean CV
and the limits of agreement were comparable
between sputum and EBC. The CR in sputum and
EBC were 54.9 and 34.0 nmol/L, respectively.
Between-day variability of MDA measurements
Sputum MDA levels measured in samples collected
on two consecutive days from the same patients were
similar (P = NS) (Supporting information Table S2).
The mean difference between the two values was
15.5 nmol/L. Although EBC MDA levels at the two
assessment points were also comparable (P = NS),
the mean difference between the measurements
increased up to 30.9 nmol/L. Moreover, the mean CV
for repeated measurements was significantly higher
and the limits of agreement markedly greater in EBC
as compared with sputum. The CR in sputum and
EBC were 43.2 and 75.1 nmol/L, respectively.
MDA in sputum
MDA levels in sputum were higher in stable COPD
patients than in healthy controls (144.6 
14.3 nmol/L vs. 85.9  11.3 nmol/L, P < 0.05; Fig. 2a).
In patients with AECOPD, sputum MDA concentra-
tions (220.0  17.5 nmol/L) were further increased
compared with stable COPD patients (P < 0.01).
MDA levels significantly decreased with treatment
(190.7  16.3 nmol/L, P < 0.05).
To further explore the changes in MDA levels
among patients with AECOPD, subjects were strati-
fied by tertiles for increases in FEV1 (DFEV1 and DFEV1
% of predicted) post-treatment (Supporting Informa-
tion Table S3 and Supporting Information Figure S1).
Patients in the highest and middle tertiles had
sputum MDA levels that were significantly decreased
at discharge compared with those at admission
(P < 0.05). By contrast, MDA concentrations did not
change during treatment (P = NS) in patients in the
lowest tertile.
MDA in EBC
EBC MDA concentrations in controls (73.1 
5.1 nmol/L), stable COPD patients (96.1 11.6 nmol/L)
and patients with AECOPD (93.3  7.6 nmol/L) were
similar (P = NS) (Fig. 2b), and treatment had no effect
on EBC MDA levels either (85.3  7.1 nmol/L,
P = NS).
Correlations between MDA and other variables
No significant correlations were observed between
sputum or EBC MDA values and FENO, lung function,
blood gas parameters or sputum total and differential
cell counts measured either in stable disease or at
exacerbation (data not shown).
DISCUSSION
This study assessed oxidative stress in the airways of
COPD patients by measuring MDA, an established
marker of lipid peroxidation in laboratory diagnos-
tics. Our results demonstrate that (i) MDA concentra-
tions in sputum are elevated in stable COPD patients
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compared with healthy controls; (ii) sputum MDA
levels are further increased in AECOPD requiring hos-
pitalization; and (iii) treatment of or recovery from
exacerbation leads to a decrease in sputum MDA
levels, primarily in those patients who have more pro-
nounced improvement in airflow limitation post-
treatment. Measurement of MDA in EBC, on the other
hand, did not appear to reflect oxidative stress within
the airways, possibly due to the high between-day
variability for this marker in EBC.
Few longitudinal studies have investigated changes
in MDA levels in the airways of patients with COPD
experiencing an exacerbation. Corradi et al. have
recently found that MDA decreases during corticos-
teroid treatment in children with an acute asthma
attack.15 Here we demonstrate that in patients with
AECOPD, levels of sputum MDA are increased com-
pared with those of stable patients. This observation
may reflect enhanced oxidant production during
AECOPD.
Sputum MDA concentrations may have decreased
after treatment. It is of interest that subgroup analysis
found that the extent of changes in MDA level is dif-
ferent among patients with various functional
improvements post-treatment. In patients who had
pronounced increases in FEV1 after therapy (highest
and middle tertiles) MDA levels were significantly
decreased at discharge. However, in patients who
experienced no or only a minor change in FEV1
(lowest tertile), MDA concentrations remained high.
Our observation that sputum MDA levels are
elevated in stable COPD compared with healthy con-
trols confirms the previous findings of Corradi et al.10
The ranges of MDA values reported in both studies are
similar.
Patients with COPD and healthy controls could not
be distinguished on the basis of MDA in EBC.
AECOPD did not increase EBC MDA either. This
finding may be due to the high between-day variabil-
ity of MDA readings in EBC. In line with this view,
considerable variability for other EBC biomarkers has
been documented in several studies.16,17 Even the pH,
which is considered to be the most robust parameter
of EBC, displays significant variation when assessed
within a short period of time in the same subjects.18
The intra- and inter-assay repeatabilities of MDA
measurements were comparable between EBC and
sputum, indicating that our detection technique is
reliable and has a similar threshold in sputum and
EBC. MDA was measured by HPLC, a very sensitive
method for analysing such compounds in aqueous
matrices.19 After sample preparation the resulting
fluorophore is highly specific and is detectable at very
low levels using a fluorescence detector. This is of par-
ticular importance because EBC is extremely diluted,
which generates a number of well-known methodo-
logical problems. Indeed, MDA was detectable in all
EBC and sputum samples. Finally, it should be noted
that our repeatability data, both CV and limits of
agreement, are smaller than those reported for other
EBC biomarkers measured by enzyme immunoassay,
such as 8-isoprostane and leukotriene B4.17
We are aware that sputum induction, as opposed to
spontaneous sputum collection, is the method of
choice in patients with mild-to-moderate COPD.20
However, as a large percentage (>60%) of our recruits
had severe or very severe COPD, spontaneous sputum
collection, rather than sputum induction, was chosen
in patients with AECOPD because of safety concerns.
As the induction by itself had no effect on MDA read-
ings, direct comparison of the two specimens was
feasible.
In line with the findings of Corradi et al.10 we did not
find correlations between sputum MDA levels and
lung function parameters or inflammatory cell counts
in our study. EBC MDA levels also did not correlate
with clinical variables. Current data are equivocal as
Figure 2 Malondialdehyde (MDA) concentrations in sputum (a)
and in exhaled breath condensate (b) of healthy controls (con-
trols), stable COPD patients (stable) and AECOPD patients at the
time of acute exacerbation (ex) and after hospital treatment
(treat). All subjects were ex-smokers. Horizontal bars represent
mean values. *P < 0.05 vs healthy controls; **P < 0.01 vs stable
COPD patients; ***P < 0.001 vs healthy controls; #P < 0.05 vs
exacerbation; §P < 0.05 vs stable COPD patients.
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to whether such a relationship exists9 or not10 in
COPD and/or asthma.
In conclusion, this study suggests that assessment
of sputum MDA, an established by-product of lipid
peroxidation, reflects exacerbation-associated oxida-
tive stress in patients with COPD. For EBC the high
day-to-day variability may limit clinical applicability.
The clinical utility of MDA measurements in the
sputum should be investigated further to clarify its
role in monitoring and to predict disease outcomes.
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Supporting Information
Additional Supporting Information may be found in the online
version of this article at the publisher’s web-site:
Figure S1 Individual changes in sputum malondialdehyde (MDA)
values in patients with acute exacerbation of chronic obstructive
pulmonary disease (AECOPD) stratified by tertiles for increases
in forced expiratory volume in one second (DFEV1 % of predicted)
post-treatment. Measurements were performed at the time of
exacerbation (ex) and at discharge after hospital treatment
(treat). Horizontal bars represent mean values. *P < 0.05 vs.
exacerbation.
Table S1 Total and differential sputum cell counts in study
subjects.
Table S2 The intra- and inter-assay repeatability and the
between-day variability of malondialdehyde (MDA) measure-
ments in sputum and exhaled breath condensate (EBC) collected
from a subset (n = 12) of stable COPD patients.
Table S3 Changes in sputum malondialdehyde (MDA) concentra-
tions in patients with acute exacerbation of chronic obstructive
pulmonary disease (AECOPD) as assessed by increases in FEV1
after treatment.
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